Click for best price
Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share 2022
Nuclear medicine, a type ofimagingthat uses radioactive materials, is a useful tool to detect and also treatprostate cancer. It is a form ofdiagnostic imagingthat helps radiologists determine the stage ofcancer.
This report contains market size and forecasts of Prostate Cancer Nuclear Medicine Diagnostics in Global, including the following market information:
The global Prostate Cancer Nuclear Medicine Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
SPECT Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Prostate Cancer Nuclear Medicine Diagnostics include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, Jubilant Pharma, NCM-USA, Progenics Pharma, Telix Pharma and ImaginAb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Prostate Cancer Nuclear Medicine Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Type, 2021 (%)
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Application, 2021 (%)
Global Prostate Cancer Nuclear Medicine Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Blue Earth Diagnostics
- PETNET Solutions
- Cardinal Health
- Lantheus Medical Imaging
- Jubilant Pharma
- NCM-USA
- Progenics Pharma
- Telix Pharma
- ImaginAb
- Theragnostics
- Novartis
- Alliance Medical
| Report Attributes |
Report Details |
| Report Title |
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
64 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Prostate Cancer Nuclear Medicine Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Prostate Cancer Nuclear Medicine Diagnostics Overall Market Size
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size: 2021 VS 2028
2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.2 Top Global Prostate Cancer Nuclear Medicine Diagnostics Companies Ranked by Revenue
3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Prostate Cancer Nuclear Medicine Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Prostate Cancer Nuclear Medicine Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Prostate Cancer Nuclear Medicine Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Markets, 2021 & 2028
4.1.2 SPECT
4.1.3 PET
4.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.3.2 US Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.4.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.4 U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.5 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.6 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.8 Benelux Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.5.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.6 India Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.6.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.6.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.7.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.3 Israel Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.5 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
7 Players Profiles
7.1 Blue Earth Diagnostics
7.1.1 Blue Earth Diagnostics Corporate Summary
7.1.2 Blue Earth Diagnostics Business Overview
7.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.1.5 Blue Earth Diagnostics Key News
7.2 PETNET Solutions
7.2.1 PETNET Solutions Corporate Summary
7.2.2 PETNET Solutions Business Overview
7.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.2.5 PETNET Solutions Key News
7.3 Cardinal Health
7.3.1 Cardinal Health Corporate Summary
7.3.2 Cardinal Health Business Overview
7.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Cardinal Health Key News
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Corporate Summary
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Lantheus Medical Imaging Key News
7.5 Jubilant Pharma
7.5.1 Jubilant Pharma Corporate Summary
7.5.2 Jubilant Pharma Business Overview
7.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Jubilant Pharma Key News
7.6 NCM-USA
7.6.1 NCM-USA Corporate Summary
7.6.2 NCM-USA Business Overview
7.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.6.5 NCM-USA Key News
7.7 Progenics Pharma
7.7.1 Progenics Pharma Corporate Summary
7.7.2 Progenics Pharma Business Overview
7.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Progenics Pharma Key News
7.8 Telix Pharma
7.8.1 Telix Pharma Corporate Summary
7.8.2 Telix Pharma Business Overview
7.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.8.5 Telix Pharma Key News
7.9 ImaginAb
7.9.1 ImaginAb Corporate Summary
7.9.2 ImaginAb Business Overview
7.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.9.5 ImaginAb Key News
7.10 Theragnostics
7.10.1 Theragnostics Corporate Summary
7.10.2 Theragnostics Business Overview
7.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.10.5 Theragnostics Key News
7.11 Novartis
7.11.1 Novartis Corporate Summary
7.11.2 Novartis Business Overview
7.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.11.5 Novartis Key News
7.12 Alliance Medical
7.12.1 Alliance Medical Corporate Summary
7.12.2 Alliance Medical Business Overview
7.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.12.5 Alliance Medical Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Prostate Cancer Nuclear Medicine Diagnostics Market Opportunities & Trends in Global Market
Table 2. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers in Global Market
Table 3. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints in Global Market
Table 4. Key Players of Prostate Cancer Nuclear Medicine Diagnostics in Global Market
Table 5. Top Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Prostate Cancer Nuclear Medicine Diagnostics Product Type
Table 9. List of Global Tier 1 Prostate Cancer Nuclear Medicine Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. Blue Earth Diagnostics Corporate Summary
Table 31. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 32. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. PETNET Solutions Corporate Summary
Table 34. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 35. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Cardinal Health Corporate Summary
Table 37. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 38. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Lantheus Medical Imaging Corporate Summary
Table 40. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 41. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Jubilant Pharma Corporate Summary
Table 43. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 44. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. NCM-USA Corporate Summary
Table 46. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 47. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Progenics Pharma Corporate Summary
Table 49. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 50. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. Telix Pharma Corporate Summary
Table 52. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 53. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 54. ImaginAb Corporate Summary
Table 55. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 56. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 57. Theragnostics Corporate Summary
Table 58. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 59. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 60. Novartis Corporate Summary
Table 61. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 62. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
Table 63. Alliance Medical Corporate Summary
Table 64. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Offerings
Table 65. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Prostate Cancer Nuclear Medicine Diagnostics Segment by Type in 2021
Figure 2. Prostate Cancer Nuclear Medicine Diagnostics Segment by Application in 2021
Figure 3. Global Prostate Cancer Nuclear Medicine Diagnostics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2021
Figure 8. By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Prostate Cancer Nuclear Medicine Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
